Sign up to our newsletter
and receive exclusive information and discount coupons straight to your inbox


Top news by writer

Daniel Tomas
Tehnology Writer

HEALTH / The daily deal : a neck massager at an unbeatable price
As of this week, helpmeoutDOC has begun offering a series of massively discounted health items for sale. Today it is time to introduce our readers…
July 28, 2016 | 0 comments

Gabriel Rosoga
Medical and Health Writer

BEAUTY & SKIN CARE / Bee venom serums work miracles on skin
Bee venom, when used in small dosis, proves to be a very effective natural medicine, with extremely beneficial impact on the human organism, with particular…
September 8, 2016 | 1 comment

Ion Gireada
Science Writer

HEALTH / Reasons why your brain hears a ringing
Brain activity in people affected by tinnitus is very different from what happens when sound is detected in brains of healthy people, new research uncovered.…
April 27, 2015 | 0 comments

Ionut Popescu
Health and lifestyle writer

HEALTH / Brits oblivious to obesity leading to cancer
British population largely unware of link between obesity and cancer, finds new survey conducted by the organization Cancer Research UK. According to the survey, 75%…
September 9, 2016 | 0 comments

New drug for Alzheimer’s looked upon with careful optimism

dependent-dementia
A new drug promoted as able to treat early stage Alzheimer’s may not be as effective as initially announced.

Aducanumab, developed by Biogen, a Cambridge, Massachusetts biotech company, acts as a monoclonal antibody, and has shown impressive results in early tests on patients with early stages of the disease. The drug reduced the amyloid plaque buildup in the brain, a commonly associated symptom in those affected by Alzheimer’s. Additional results in the tests showed a reduction of cognitive decline and dementia.

According to the Mini Mental Status Exam, people at risk of Alzheimer’s who got a placebo lost around 3 points over a year. In contrast, those participants who got the lowest dose of aducanumab worsened by just two points, and those who got a higher dose lost less than a point.

The study involved 166 volunteers, and prompted the company to immediately move to a much bigger clinical trial. There is no doubt that many would be extremely excited by the prospect of an Alzheimer’s treatment, but there are more questions lurking beneath the surface.

In the U.S. about 5 million people have Alzheimer’s. A pill that could offer those people some extra time with their loved ones is regarded as an important step forward. However, there is no guarantee that this will lessen the fear surrounding the disease, or if it will even effectively stop the dying process.

The treatment also calls into question many ethical debates, such as who will get the pill and why. If such a cure existed, it is not guaranteed that it would be available to everyone.

Furthermore, the cost is another important aspect of the matter, not to mention whether living longer with the disease is in fact such a good thing.

Currently, family members of patients of Alzheimer’s have reasons to be happy about, but later tests and provide answers to these concerns.



New drug for Alzheimer’s looked upon with careful optimism



dependent-dementia
facebook pinterest google+